Study Title
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease (NCT01616680)
Trial Description
The purpose of this research is to test the safety and efficacy of brentuximab vedotin (also known as SGN-035) in patients with acute skin graft-versus-host disease or GVHD.
This trial is sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium/ National Cancer Institute (NCI) [1]
Study Data
- Condition: Graft vs. Host Disease (GVHD)
- Interventions:
- Drugs used in this trial
- brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- Drugs used in this trial
- Phase: II
- Enrollment: 0
- Start: September 2012
- Estimated Primary Completion: June 2016 (Final data collection date for primary outcome measure)
- Last verified: June 2013
Study Schematic
Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
